This function was confirmed by means of both pharmacological inhibition studies, where JAK inhibitor I and a JAK2-specific inhibitor prevented OM-mediated PCSK9 suppression, and siRNA-mediated silencing of JAK1 and JAK2, which restored PCSK9 expression in OM-treated cells [21, 68]. Here, JAK2 is linked to ocular melanoma.